SCHEDULE: Lynx1 Capital Resubmits $4.75/Share Offer for Neuphoria

Lynx1 Capital Management LP has submitted a recalculated non-binding proposal to acquire Neuphoria Therapeutics Inc. for $4.75 per share in cash, adjusting for recent share dilution.

Summary

• Lynx1 Capital Management LP and Weston Nichols, who beneficially own 16.3% of Neuphoria Therapeutics Inc.'s common stock, have submitted a recalculated non-binding proposal to acquire all outstanding shares for $4.75 per share in cash.
• This offer supersedes an initial non-binding offer made on November 10, 2025, which was withdrawn on November 18, 2025.
• The withdrawal and recalculation were prompted by Neuphoria's public disclosures on November 14, 2025, revealing a 128% increase in outstanding shares over four weeks to 5,377,329 as of November 13, 2025, and plans to register an additional $20 million in securities.
• The recalculated offer aims to preserve the "all-in economics" of the initial offer, adjusted for the increased share count, Neuphoria's cash balance, and spending on its proxy contest defense.
• The $4.75 per share represents a 16% premium over Neuphoria's closing stock price on Nasdaq on November 7, 2025, which is lower than the 27% premium of the initial offer due to the Board's actions.
• Key assumptions for the offer include no further share issuances, 5,377,329 shares outstanding at closing, and approximately $28 million in net unrestricted cash and cash equivalents at closing.
• Lynx1 has sufficient capital, and financing will not be a condition or cause delay for the acquisition.
• Lynx1 is also open to acquiring a select asset of the Company, subject to due diligence on collaboration partner and licensee agreements.
• The proposal is non-binding, and definitive obligations would only arise upon entering into formal agreements.

Sentiment

Score: 6

Explanation: The filing presents a concrete acquisition offer at a premium, which is generally positive for shareholders. However, the offer is non-binding, the premium is lower than the initial offer due to company actions, and it comes with specific assumptions and risks related to cash balance and future share issuances. The activist nature and the company's prior dilution also add a layer of uncertainty.

Positives

• A new, specific all-cash acquisition proposal of $4.75 per share has been made for Neuphoria Therapeutics Inc.
• The offer represents a 16% premium over the closing price of Neuphoria's common stock on November 7, 2025.
• Lynx1 Capital Management LP has sufficient capital available, and financing will not delay the process or be a condition for closing the acquisition.
• Lynx1 is willing to explore alternative transactions, such as acquiring a select asset of the Company, if preferred by stockholders.

Negatives

• The per-share premium of 16% is lower than the 27% premium of the initial offer, which Lynx1 attributes directly to the Board's actions since their initial proposal.
• The offer is non-binding and does not create any binding obligations until definitive agreements are signed.
• The offer is contingent on several assumptions, including no additional share issuances during the strategic-review process and a projected net unrestricted cash balance of approximately $28 million at closing.
• Any delays in consummating the acquisition that result in a reduction in the actual amount of net unrestricted cash could lead to a reduction in the acquisition price.

Risks

• Any delays in consummating the acquisition that result in a reduction in the actual amount of net unrestricted cash could lead to a reduction in the acquisition price.
• The proposal is non-binding and does not create a binding obligation; definitive agreements are required for any transaction to proceed.
• The offer is based on specific assumptions, including no additional share issuances and a particular cash balance, which if not met, could impact the offer terms or viability.

Future Outlook

Lynx1 Capital Management LP's proposal indicates a clear intent to acquire Neuphoria Therapeutics Inc., either entirely or a select asset, contingent on the company's response by December 5, 2025, and adherence to specific financial conditions regarding share count and cash balance. The future outlook for Neuphoria is highly dependent on its Board's decision regarding this non-binding offer and potential negotiations.

Management Comments

• "We have continued to stand behind the economics of our Initial Offer, but the Company's share issuances since our Initial Offer made it impossible for us to determine a specific offer price that would capture the economics of those issuances."
• "We understand however from the Company's recent public disclosures that it has now ceased issuing new shares, and so we are pleased to submit a recalculated non-binding indication of interest."
• "This Recalculated Initial Offer preserves the all-in economics of the Initial Offer, as adjusted for share issuances since October 27, 2025, the Company's more recent cash balance figure (as projected by us, based on the Company's public filings subsequent to the Initial Offer), and the Company's continued spending in defense of its proxy contest with us."
• "This is lower (on a per share basis) than the 27% premium of the Initial Offer due (directly) to the Board's actions since our Initial Offer."
• "Because our proposal includes an assumption about the amount of the Company's net unrestricted cash at the Acquisition closing, any delays to our consummating the Acquisition that result in a reduction in the actual amount of net unrestricted cash could in turn result in a reduction in our Acquisition price."
• "As with our Initial Offer, because we have sufficient capital available to us to fund the Acquisition, our ability to secure financing will not delay our process and will not be a condition for us to close the Acquisition."
• "We believe that this proposal represents a highly beneficial outcome for the Company and its stockholders and are excited by the potential benefits that the Acquisition would yield for all stakeholders."

Industry Context

This filing highlights ongoing shareholder activism and M&A activity within the biotechnology sector, where smaller companies like Neuphoria Therapeutics Inc. can become targets for acquisition, especially when facing financial challenges or strategic uncertainties. The emphasis on share dilution and cash balances reflects common concerns for investors in growth-stage biotech firms, where capital raises and burn rates significantly impact valuation. Lynx1 Capital's persistent pursuit, despite previous withdrawals, suggests a strong belief in the underlying value of Neuphoria's assets, potentially indicating a broader trend of strategic consolidation or asset-focused acquisitions in the industry.

Stakeholder Impact

• Shareholders: Potential for an all-cash acquisition at a premium, offering liquidity and a defined exit price. However, the offer is non-binding and subject to conditions, and the premium is lower than initially proposed due to prior dilution.
• Management/Board: Under pressure to evaluate the offer and respond by the deadline, potentially engaging in negotiations or defending against the proposal. The filing explicitly mentions "continued spending in defense of its proxy contest."
• Employees: Potential for changes in company structure or ownership if the acquisition proceeds, which could impact employment.
• Collaboration Partners/Licensees: If an asset acquisition is pursued, the terms of existing agreements would be subject to due diligence to ensure continuity.

Next Steps

• Neuphoria Therapeutics Inc.'s Board of Directors to consider the recalculated non-binding proposal.
• Neuphoria Therapeutics Inc. to respond to Lynx1 Capital Management LP by 12:00 p.m. (noon), New York time, on December 5, 2025.
• Potential engagement between Lynx1 Capital Management LP and Neuphoria Therapeutics Inc. and their advisors.
• Potential negotiation and execution of definitive purchase and related agreements for the acquisition.
• Potential due diligence by Lynx1 Capital Management LP if an asset acquisition is pursued.

Key Dates

Recommendation

The filing presents a non-binding acquisition offer at a 16% premium, which could be attractive. However, the offer is conditional on no further dilution and a specific cash balance, and the premium is lower than the initial offer due to the company's prior actions. Given the non-binding nature and the short deadline for response, investors should hold to see how the Board of Directors responds and if a definitive agreement materializes. The situation is fluid, with potential for negotiation or rejection, making a 'buy' or 'sell' premature without further clarity.

Keywords

Neuphoria Therapeutics, Lynx1 Capital Management, Acquisition Proposal, Shareholder Activism, Schedule 13D, Cash Offer, Biotechnology M&A, Equity Dilution, Corporate Governance, Takeover Bid